Mouse Anti-FTO Recombinant Antibody (CBXF-1805) (CBMAB-F3340-CQ)

Basic Information
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Specifically demethylates N6-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed:22002720, PubMed:26458103, PubMed:30197295, PubMed:26457839, PubMed:25452335).
M6A demethylation by FTO affects mRNA expression and stability (PubMed:30197295).
Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed:30197295).
Mediates demethylation of N6,2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N6-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed:28002401, PubMed:30197295).
Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping (PubMed:28002401).
Also acts as a tRNA demethylase by removing N1-methyladenine from various tRNAs (PubMed:30197295).
Has no activity towards 1-methylguanine (PubMed:20376003).
Has no detectable activity towards double-stranded DNA (PubMed:20376003).
Also able to repair alkylated DNA and RNA by oxidative demethylation: demethylates single-stranded RNA containing 3-methyluracil, single-stranded DNA containing 3-methylthymine and has low demethylase activity towards single-stranded DNA containing 1-methyladenine or 3-methylcytosine (PubMed:18775698, PubMed:20376003).
Ability to repair alkylated DNA and RNA is however unsure in vivo (PubMed:18775698, PubMed:20376003).
Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation (PubMed:18775698, PubMed:20376003).
Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells (PubMed:26287746).
Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs (By similarity).
Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation: acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression (PubMed:28017614, PubMed:29249359).
DNA dealkylation involved in DNA repair Source: UniProtKB
DNA demethylation Source: BHF-UCL
mRNA destabilization Source: UniProtKB
Oxidative demethylation Source: BHF-UCL
Oxidative single-stranded DNA demethylation Source: UniProtKB
Oxidative single-stranded RNA demethylation Source: UniProtKB
Regulation of brown fat cell differentiation Source: UniProtKB
Regulation of lipid storage Source: UniProtKB
Regulation of multicellular organism growth Source: Ensembl
Regulation of respiratory system process Source: Ensembl
Regulation of white fat cell proliferation Source: Ensembl
RNA repair Source: BHF-UCL
Temperature homeostasis Source: Ensembl
A severe polymalformation syndrome characterized by postnatal growth retardation, microcephaly, severe psychomotor delay, functional brain deficits and characteristic facial dysmorphism. In some patients, structural brain malformations, cardiac defects, genital anomalies, and cleft palate are observed. Early death occurs by the age of 3 years.
Obesity (OBESITY):
Disease susceptibility is associated with variants affecting the gene represented in this entry. It is unclear whether variations associated with obesity directly affect FTO function or alter the expression of adjacent genes such as IRX3, rather than FTO itself (PubMed:24646999, PubMed:26287746). A pathogenic intronic FTO variation (rs1421085) disrupts an evolutionarily conserved motif for ARID5B binding (PubMed:26287746). Loss of ARID5B binding results in overexpression of two genes distal to FTO, IRX3 and IRX5. IRX3 and IRX5 overexpression shifts pre-adipocytes differentiation from brown to white fat cells, resulting in increased lipid storage and loss of mitochondrial thermogenesis (PubMed:26287746). A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols
Related Products
Mouse Anti-FTO Recombinant Antibody (FT62-6) (CAT#: CBMAB-F2968-CQ)
Rabbit Anti-FTO Recombinant Antibody (CBXF-1236) (CAT#: CBMAB-F0988-CQ)
Mouse Anti-FTO Recombinant Antibody (FT86-4) (CAT#: CBMAB-F1337-CQ)
Rat Anti-FTO Recombinant Antibody (FT342-1) (CAT#: CBMAB-F2969-CQ)
Mouse Anti-FTO Recombinant Antibody (CBXF-2684) (CAT#: CBMAB-F3091-CQ)
Rabbit Anti-FTO Recombinant Antibody (D2V1I) (CAT#: CBMAB-CP0771-LY)
Mouse Anti-FTO Recombinant Antibody (AG103) (CAT#: CBMAB-F2496-CQ)
Rabbit Anti-FTO Recombinant Antibody (CBNH-050) (CAT#: CBMAB-R4375-CN)
Rabbit Anti-FTO Recombinant Antibody (CBXF-1235) (CAT#: CBMAB-F0203-CQ)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
